ESCRS - PO071 - Agreement Of Tear Break-Up Time And Meniscus Height Between Medmont E300 And Visionix Vx120+

Agreement Of Tear Break-Up Time And Meniscus Height Between Medmont E300 And Visionix Vx120+

Published 2022 - 40th Congress of the ESCRS

Reference: PO071 | Type: ESCRS 2022 - Posters | DOI: 10.82333/gz8k-f982

Authors: Elena Martínez-Plaza 1 , Ainhoa Molina-Martín 2 , Sidi Mohamed Hamida Abdelkader 3 , David Pablo Piñero Llorens* 2

1Department of Optics, Pharmacology and Anatomy,University of Alicante,Alicante,Spain;University of Valladolid,Valladolid,Spain, 2Department of Optics, Pharmacology and Anatomy,University of Alicante,Alicante,Spain, 3Department of Ophthalmology,Torrecárdenas Hospital,Almeria,Spain

Purpose

To analyze the agreement between the corneal topographer Medmont E300 and the multi-diagnostic platform Visionix VX120+ in the non-invasive tear break-up time (NIBUT) and tear meniscus height (TMH) measurements.

Setting

Optometry Clinic of the University of Alicante, Spain. Department of Optics, Pharmacology and Anatomy, University of Alicante, Spain.

Methods

A total of 60 eyes (30 healthy subjects) were enrolled. NIBUT and TMH were evaluated with Medmont E300; first NIBUT, NIBUT50% and TMH were evaluated with Visionix VX120+. Both evaluations were performed in a random order by the same clinician. Statistical analysis was performed for right, left and both eyes. As normality could not be assumed, the agreement was analyzed by the Wilcoxon test and the Passing-Bablok regression. The relationship between parameters was analyzed using the Spearman rank correlation.

Results

Subjects enrolled presented a mean spherical equivalent of -2.58 ± 3.06 diopters and a mean corrected distance visual acuity of -0.06 ± 0.15 logMAR. The Medmont E300 provided significantly higher NIBUT than Visionix VX120+ for first NIBUT (p ≤ 0.003) in all situations (right, left and both eyes) and NIBUT50% in left and both eyes (p ≤ 0.042). The TMH measured with VX120+ was significantly higher than the one measured with Medmont E300 considering both eyes (p = 0.037). No significant correlations were found between both devices for neither NIBUT (p ≥ 0.11) nor TMH (p ≥ 0.09) outcomes. Passing-Bablok regression analysis revealed that there was a very poor agreement between devices for both NIBUT and TMH outcomes.

Conclusions

Very limited agreement was observed between Medmont E300 and Visionix VX120+ for NIBUT and TMH outcomes. Indeed, VX120+ is expected to provide substantial lower first NIBUT values than the NIBUT measured by Medmont E300. Clinicians should consider not using both instruments interchangeable for dry eye diagnosis.